Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 20/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 17/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169865 | 0.94 | ABCG2 (0.90) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7170174 | 0.94 | ABCG2 (1.00) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7170870 | 0.93 | ABCG2 (0.89) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7170917 | 0.93 | ABCG2 (0.88) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7169098 | 0.93 | ABCG2 (0.88) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL29387641 | 0.93 | ABCG2 (1.00) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7172809 | 0.92 | ABCG2 (0.87) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7168517 | 0.92 | ABCG2 (0.86) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7168503 | 0.92 | ABCG2 (0.86) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 | |
| SCHEMBL7171159 | 0.91 | ABCG2 (0.85) | ABCG2ABCB1CYP1A2CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934276-B1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LTD (GB) | 2003-12-17 | — | — | EP | claimed |
| US-6218393-B1 | IN THERAPY OF MULTIDRUG RESISTANT CANCERS, FOR EXAMPLE TO POTENTIATE CYTOTOXICITY OF CANCER DRUG | XENOVA LIMITED (GB) | 2001-04-17 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-1241181-A | Pharmaceutical compounds | XENOVA LTD (GB) | 2000-01-12 | — | — | CN | disclosed |